Trial Profile
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Tavokinogene telseplasmid (Primary) ; Nivolumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 04 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 01 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Feb 2024.